Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Asset Writedowns and Impairment: 2014-2024

Historic Asset Writedowns and Impairment for Theravance Biopharma (TBPH) over the last 5 years, with Dec 2024 value amounting to $4.5 million.

  • Theravance Biopharma's Asset Writedowns and Impairment was N/A to $1.6 million in Q3 2024 from the same period last year, while for Sep 2024 it was $10.3 million, marking a year-over-year change of. This contributed to the annual value of $4.5 million for FY2024, which is N/A change from last year.
  • Per Theravance Biopharma's latest filing, its Asset Writedowns and Impairment stood at $4.5 million for FY2024, which was up 509.86% from $740,000 recorded in FY2017.
  • Theravance Biopharma's 5-year Asset Writedowns and Impairment high stood at $4.5 million for FY2024, and its period low was $4.5 million during FY2024.
  • Its 1-year average for Asset Writedowns and Impairment is $4.5 million, with a median of $4.5 million in 2024.